title: No evidence for proliferation in the blood CD4+ T-cell pool during HIV-1 infection and triple combination therapy.
abstract: OBJECTIVE
  To evaluate the role of cell proliferation in peripheral blood lymphocyte (PBL) dynamics during HIV infection and potent antiretroviral therapy including protease inhibitors.
  
  
  METHODS
  Transverse study of 150 patients at different stages of infection. Longitudinal study of 50 patients on triple combination antiretroviral therapy with 9-month follow-up.
  
  
  METHODS
  Ex vivo incubation of fresh PBL with the DNA biosynthetic marker bromodeoxyuridine (BrdU). Flow cytometric analysis of cell phenotypes and BrdU incorporation. Parallel determination of plasma virus load and CD4+ cell counts.
  
  
  RESULTS
  Percentages of BrdU+ B and T lymphocytes found in patients with asymptomatic HIV infection were not different from the low values found in HIV-seronegative controls, and were not correlated with the CD4+ cell count. DNA synthesis increased significantly only during acute opportunistic infections occurring in patients with high plasma viral load and fewer than 100 x 10(6) CD4+ cells/l. Triple combination therapy induced a decrease of plasma virus load and a rise of CD4+ cell counts, whereas BrdU incorporation remained low or decreased.
  
  
  CONCLUSIONS
  Proliferation of peripheral blood T cells observed at late stages of HIV infection corresponds to a response to opportunistic infections. Apart from these particular cases, proliferation in this compartment does not appear as a critical parameter of CD4+ cell kinetics during chronic HIV infection and potent therapy.
authors.affiliation: INSERM U345, Institut Necker, Paris, France.
authors.forename: O
authors.initials: O
authors.lastname: Tissot
authors.forename: J P
authors.initials: JP
authors.lastname: Viard
authors.forename: C
authors.initials: C
authors.lastname: Rabian
authors.forename: N
authors.initials: N
authors.lastname: Ngo
authors.forename: M
authors.initials: M
authors.lastname: Burgard
authors.forename: C
authors.initials: C
authors.lastname: Rouzioux
authors.forename: C
authors.initials: C
authors.lastname: Penit
mesh_terms: D019380:Anti-HIV Agents / Q000627:therapeutic use*; D001973:Bromodeoxyuridine / Q000378:metabolism; D018791:CD4 Lymphocyte Count; D015496:CD4-Positive T-Lymphocytes / Q000166:cytology / Q000276:immunology* / Q000378:metabolism; D002455:Cell Division; D004247:DNA / Q000096:biosynthesis; D004359:Drug Therapy, Combination; D005434:Flow Cytometry; D005500:Follow-Up Studies; D015658:HIV Infections / Q000188:drug therapy* / Q000276:immunology; D015497:HIV-1; D006801:Humans; D008137:Longitudinal Studies; D008213:Lymphocyte Activation / Q000187:drug effects*; D012367:RNA, Viral / Q000097:blood; D019562:Viral Load
chemical_list: D019380:Anti-HIV Agents; D012367:RNA, Viral; D004247:DNA; D001973:Bromodeoxyuridine